1242087-93-9
Chemical Structure
Ravidasvir
Synonym(s): PPI-668
- CAS No.: 1242087-93-9
- Formula:C42H50N8O6
- Molecular Weight:762.91
IUPAC Name: methyl ((S)-1-((S)-2-(6-(6-(2-((S)-1-((methoxycarbonyl)-L-valyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)naphthalen-2-yl)-1H-benzo[d]imidazol-2-yl)pyrrolidin-1-yl)-3-methyl-1-oxobutan-2-yl)carbamate
InChIKey: LCHMHYPWGWYXEL-ZYADHFCISA-N
SMILES: C([C@@H](NC(OC)=O)C(C)C)(=O)N1[C@H](C=2NC=3C(N2)=CC=C(C3)C4=CC5=C(C=C4)C=C(C=C5)C=6NC(=NC6)[C@H]7N(C([C@@H](NC(OC)=O)C(C)C)=O)CCC7)CCC1
Biological Activity: Ravidasvir (PPI-668) is an orally active pan-genotypic NS5A inhibitor and antiviral agent. Ravidasvir exhibits antiviral activity against HCV genotypes 1 to 6, with EC50 values ranging from 0.04 to 1.14 nM. Ravidasvir shows no or extremely low activity against feline infectious peritonitis virus type II. Ravidasvir can be used in research related to hepatitis C virus infection[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Ravidasvir | Ravidasvir (PPI-668) is an orally active pan-genotypic NS5A inhibitor and antiviral agent. Ravidasvir exhibits antiviral activity against HCV genotypes 1 to 6, with EC50 values ranging from 0.04 to 1.14 nM. Ravidasvir shows no or extremely low activity against feline infectious peritonitis virus type II. Ravidasvir can be used in research related to hepatitis C virus infection. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Hefnawy M, et al. Validated Microwell-Based Spectrofluorimetric Method for Quantification of Ravidasvir (New Anti-Chronic Hepatitis C Virus-GT4) in Rat Plasma and Its Application to Pharmacokinetic Study. Drug Des Devel Ther. 2020;14:4377-4385. Published 2020 Oct 20. [Content Brief]
- [2]. Wu G, et al. Pharmacokinetics, Safety, and Tolerability of Ravidasvir, with and without Danoprevir/Ritonavir, in Healthy Subjects. Antimicrob Agents Chemother. 2021;65(10):e0060021. [Content Brief]
- [3]. Cook SE, et al. Investigation of monotherapy and combined anticoronaviral therapies against feline coronavirus serotype II in vitro. J Feline Med Surg. 2022;24(10):943-953. [Content Brief]
Keywords
